-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57

Benzinga·07/16/2026 09:46:04
语音播报
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.